AbbVie had a strong Q1 performance in its oncology, neuroscience, and immunology franchises. Read why I continue to rate ABBV ...

AbbVie (ABBV) delivered impressive financial results for the first quarter of 2025. Investors responded enthusiastically, ...

AbbVie Inc.'s Q1 earnings highlight an 8.4% revenue boost, driven by Skyrizi & Rinvoq. Click for ABBV's market expansion, ...

A technological revolution is helping Scripps Research scientists see the molecules that undermine human health, from ...

Humira can lower immune system activity, increasing the risk of serious infection and cancer. Taking steps to support your immune health can help you stay well during Humira treatment. Talk with ...

Humira has a boxed warning for the risk of cancer during treatment. A boxed warning is the most serious warning from the FDA. It’s important to watch for any symptoms of cancer during your ...

We recently published a list of Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential. In this article, we are going to take a look at where AbbVie Inc.

Flyers urge consumers to take action beneficial to the pharmaceutical industry. But the campaign completely misses the bigger ...

Sanofi’s development of an oral spin on Humira’s mechanism has hit a setback. | Sanofi’s development of an oral spin on ...

Jonathan Rockoff is the Health Business editor at The Wall Street Journal, managing a team that reports on pharmaceutical and biotechnology companies, health insurers and hospitals. During the ...

Merck MRK and AbbVie ABBV are leading pharmaceutical companies with strong portfolios in oncology and immunology. While ...

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.